Article Text

Download PDFPDF
976 The impact of Covid-19 on the care of endometrial and ovarian cancer: a population-based study in the Netherlands
  1. Eline Oymans1,
  2. Cor De Kroon2,
  3. Joost Bart3,
  4. Hans Nijman3 and
  5. Maaike Van Der Aa1
  1. 1Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, The Netherlands
  2. 2Leiden University Medical Center, Leiden, The Netherlands
  3. 3University Medical Center Groningen, Groningen, The Netherlands


Introduction/Background We aimed to study the impact of the COVID-19 pandemic on patient and treatment characteristics of both endometrial and ovarian cancer in the Netherlands.

Methodology Data of the Netherlands Cancer Registry was used to perform a retrospective cohort study on women of 18+ years diagnosed with invasive endometrial (EC) or epithelial ovarian cancer (OC) in the period 2017–2021. Patient characteristics, tumour stage at diagnosis, types of treatment, waiting periods for treatment and referral patterns in the period before the COVID-19 pandemic (BC; 2017–2019), during the pandemic (2020) and after the first year of the pandemic (2021) were assessed.

Results No stage shift was noticed for both EC and OC. For EC, fewer patients received surgery (87.6% BC, 84.6% 2020, 85.8% 2021, p=0.02) and more patients received primary hormone therapy in 2020 and 2021 compared to the period BC (4.2% BC, 5.9% 2020, 5.6% 2021, p=0.03). The waiting time between the first consultation and time of first surgery was shorter in 2020 and 2021 (p<0.01) and the waiting time between surgery and adjuvant radiotherapy was longer in 2021 (p=0.02). For OC, a higher number of patients received more than 3 cycles of platinum-based neoadjuvant chemotherapy in 2020 and 2021 compared with BC. (23.1%, 30.4%, 20.6% respectively, p=0.01). For OC the mean waiting time between first consultation and neoadjuvant chemotherapy was lower in 2020 (p=0.02).

Conclusion Although the COVID pandemic had a profound impact on the society and the delivery of health care in general, there was a minimal impact on tumour characteristics associated with outcome, in patients with EC and OC during the pandemic and after the first year following the pandemic in the Netherlands. It will be a few years before the impact of the COVID-19 pandemic on progression-free survival and overall survival can be assessed.

Disclosures The authors do not have any conflict of interest to declare.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.